Ceribell, Inc., a Mountain View, CA-based developer of a non-invasive brain monitor, completed a $53m Series C financing.
The round was co-led by Longitude Capital and The Rise Fund with participation from new investors RA Capital Management, Redmile Group and Red Tree Venture Capital, with existing shareholders.
The company will use the funds to further expand its commercial presence in emergency departments and intensive care units globally.
The Ceribell® technology platform is designed to address the need for faster diagnosis in patients with suspicion of seizure.
Led by Jane Chao, CEO and Co-Founder, Ceribell provides an FDA cleared, point of care brain monitor that uses real-time cloud computing and the proprietary Clarity™ machine learning algorithm to provide rapid answers at the bedside for immediate and precise treatment. The Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States.